News

OBI Pharma, Inc. to Present at the J.P. Morgan Healthcare Conference

SAN FRANCISCO, CA. January 8, 2019 /PRNewswire/ — OBI Pharma, Inc., …

OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer

First Orphan Drug Designation for OBI-888, a novel first-in-class Monoclonal …

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)

Second Orphan Drug Designation for OBI-3424, a novel first-in-class targeted …

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)

First Orphan Drug Designation for OBI-3424, a novel first-in-class targeted …

OBI Pharma Announces FDA Clearance of OBI-3424 IND Application for A Phase I/II Study Targeting AKR1C3 Solid Tumors

First clinical trial to test the safety and efficacy of …

OBI Pharma Announces FDA Clearance Of IND Application For A Phase 1 Study Of A Monoclonal Antibody Cancer Immunotherapy (OBI-888)

First Clinical Trial to Test the Safety and Preliminary Activity …

OBI Pharma announces participation at the 36th J.P. Morgan Annual Healthcare Conference in San Francisco from January 8-10, 2018.

Taipei, Taiwan, December 22, 2017 6:00pm – OBI Pharma, Inc. …

OBI Pharma announces OBI-3424 results from the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Study finds OBI-3424 exerts profound in vivo efficacy and safety …

OBI Pharma Announces Presentation on OBI-3424 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Poster presentation to reveal data regarding in vivo efficacy against …

Licensing agreement of ThioBridge™ signed with Abzena (AIM: ABZA)

OBI Pharma (‘OBI’, TPEx: 4174) has signed a licensing agreement …